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Abstract
Background: Oestrogen receptor (ER) positive (luminal) tumours account for the largest proportion of females with breast
cancer. Theirs is a heterogeneous disease presenting clinical challenges in managing their treatment. Three main biological
luminal groups have been identified but clinically these can be distilled into two prognostic groups in which Luminal A are
accorded good prognosis and Luminal B correlate with poor prognosis. Further biomarkers are needed to attain
classification consensus. Machine learning approaches like Artificial Neural Networks (ANNs) have been used for
classification and identification of biomarkers in breast cancer using high throughput data. In this study, we have used an
artificial neural network (ANN) approach to identify DACH1 as a candidate luminal marker and its role in predicting clinical
outcome in breast cancer is assessed.
Materials and methods: A reiterative ANN approach incorporating a network inferencing algorithm was used to identify ER-
associated biomarkers in a publically available cDNA microarray dataset. DACH1 was identified in having a strong influence
on ER associated markers and a positive association with ER. Its clinical relevance in predicting breast cancer specific survival
was investigated by statistically assessing protein expression levels after immunohistochemistry in a series of unselected
breast cancers, formatted as a tissue microarray.
Results: Strong nuclear DACH1 staining is more prevalent in tubular and lobular breast cancer. Its expression correlated
with ER-alpha positive tumours expressing PgR, epithelial cytokeratins (CK)18/19 and ‘luminal-like’ markers of good
prognosis including FOXA1 and RERG (p,0.05). DACH1 is increased in patients showing longer cancer specific survival and
disease free interval and reduced metastasis formation (p,0.001). Nuclear DACH1 showed a negative association with
markers of aggressive growth and poor prognosis.
Conclusion: Nuclear DACH1 expression appears to be a Luminal A biomarker predictive of good prognosis, but is not
independent of clinical stage, tumour size, NPI status or systemic therapy.
Citation: Powe DG, Dhondalay GKR, Lemetre C, Allen T, Habashy HO, et al. (2014) DACH1: Its Role as a Classifier of Long Term Good Prognosis in Luminal Breast
Cancer. PLoS ONE 9(1): e84428. doi:10.1371/journal.pone.0084428
Editor: Arun Rishi, Wayne State University, United States of America
Received May 29, 2013; Accepted November 14, 2013; Published January 2, 2014
Copyright:  2014 Powe et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study received financial support from the John and Lucille van Geest Foundation. The funder had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: des.powe@nottingham.ac.uk
. These authors contributed equally to this work.
Introduction
Breast cancer is the most common cancer in females and the
third most common cause of cancer death in the UK after lung
and large bowel cancer [1]. Recent studies have confirmed the
heterogeneity of breast cancer arising from inherited and acquired
genetic variation. It has recently been proposed that 10 molecular
breast cancer groups exist [2], building on the overarching and
simpler four group molecular stratification established more than a
decade ago [3–6]. The largest of these groups comprise oestrogen
receptor (ER) positive (luminal) tumours with the latest evidence
suggesting complex clinical diversity and mortality risk [2]. It has
long been appreciated that the oestrogen receptor has a
compelling role in breast cancer biology because its expression is
both a predictive and independent prognostic factor for disease
outcome, treatment response and recurrence in breast cancer [7].
This is because when activated it induces pro-cancerous cell
signalling pathways, influencing cell growth, survival and differ-
entiation.
Gene expression array data has shown the luminal family of
breast cancer includes at least one high risk subgroup, several
intermediate risk subgroups (including a luminal B subgroup), and
two good prognosis subgroups comprising a ‘pure’ ER luminal A
subgroup and a mixed ER positive/negative subgroup [2].
Improved classification delivering clinical utility is required to
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achieve more effective therapeutic treatment and to identify
patients that will be refractory to anti-hormonal therapy. Luminal
A tumours tend to be low grade tumours that are characterised by
over expression of ER-activating genes including LIV1, CCND1,
FOXA1, XBP1, GATA3 and Bcl-2 [8]. Contrasting with this,
luminal B cancers are high grade, show increased proliferation
(Ki67 positive) and growth factor receptors such as EGFR, and
have variable HER2 expression [9]. A number of studies have
attempted to phenotype luminal subgroups using protein bio-
markers with immunohistochemistry, and to relate these to
increased risk of adverse events. For example the transferrin
receptor, CD71, is involved in the uptake of iron and is expressed
on cells showing high proliferation, and previously we reported it
to be an independent prognosticator of an ER+ subgroup
characterised by poor prognosis and resistance to endocrine
therapy [10]. Another example is the proliferation related marker
TK1 which is an enzyme involved in the synthesis of thymidine
triphosphate needed by the proliferating cells to enter S phase
[11]. In addition, CARM 1 [12] and PELP1 are transcriptional
corepressors and indicators of reduced disease free survival in
luminal cancers [13]. PELP1 is a coactivator that binds with the
AF-2 domain (oestrogen responsive element) of ERa, facilitating
downstream estradiol-induced DNA synthesis and cell prolifera-
tion [14].
In recent times, various computational approaches have been
developed for cancer classification and diagnosis prediction [15].
In breast cancer hierarchical clustering analysis of gene expression
array data has proven useful in providing broad molecular
classification [3], but other techniques are required to identify
biomarkers defining membership to various subgroups. Subse-
quently, computer algorithms incorporating a multilayer percep-
tron based Artificial Neural Network (ANN) method [16] have
been adopted to identify cancer-relevant biomarkers to assist in
clinical decision-making [17,18]. Previously ANN has been used to
identify a panel of protein biomarkers [19] capable of classifying
breast cancer patients parallel to that achieved using gene
expression profiling [3]. ANNs have proved to be capable of
modelling biological systems more precisely than conventional
statistical techniques [20], and are successful for avoiding over-
fitting and to produce generalised models with validation subsets in
breast cancer dataset [21].
In this study we used an ANN based network inference
approach [22] to identify ER-associated biomarkers with the aim
of improving classification of luminal breast cancer group based on
cancer specific survival. Seventeen candidate genes were identified
including the Drosophila dachshund (dac) gene. DACH1 belongs
to the nuclear protein family undertaking a vital role in promoting
differentiation of Drosophila eye and limb and retinal determina-
tion signalling pathway [23,24]. In humans, DACH1 is known to
repress tumorigenesis in human breast and prostate cancers [25]
and down regulates EGFR and cyclin D1 in tumour cells [26].
Furthermore, DACH1 may control stem cell gene expression [27]
preventing cancer cell migration needed for metastasis develop-
ment [28]. DACH1 was selected for further study because it is
hypothesised that high levels of DACH1 will competitively inhibit
the growth promoting activity of PELP1 and consequently will be
associated with improved prognosis. The current study aims to
characterise the association of DACH1 with other cancer relevant
biomarkers in the luminal subtype of breast cancer, with the
emphasis being in determining its possible role as a clinical
classifier of disease outcome and as a prognostic biomarker.
Materials and Methods
This study was approved by the Nottingham Research Ethics
Committee 2 under the title ‘Development of a molecular genetics
classification of breast cancer’.
Breast cancer microarray dataset
To identify genes associated with ER status in breast cancer a
cDNA microarray dataset, E-GEOD-20194 [29], was selected
from the public repository ArrayExpress [30], submitted by Micro
Array Quality Control consortium. The dataset comprises
expression values for 22,283 probe sets targeting gene transcripts
across 278 samples (ER positive = 164 and ER negative = 114)
with tumour stage ranging from I-III.
ANN architecture and model development
The ANN architecture encompasses supervised learning from a
multilayer perceptron model employing two hidden nodes with a
sigmoidal transfer function. The samples were subjected to Monte
Carlo Cross Validation strategy by randomly segregating them
into three different subsets namely: train (to perform learning), test
(for early stopping when the network fails to perform better with a
threshold of 3000 epochs or 1000 epochs without improvement in
mean square errors (MSE) and validation subsets (to authenticate
the model performance on previously unseen data) in a proportion
of 60%, 20% and 20% respectively. Each of the 22,283 probe sets
were used as individual input variables in the model. The
algorithm used a momentum of 0.5 and learning rate of 0.1.
The error differences in actual and predicted values were used to
update the weights with a back propagation algorithm. The
complete ANN model is reiterated 50 times with random
sampling. Across 50 ANN model predictions, the average MSE
of a test subset for each input variable was considered to determine
their predictive capability for ER class.
Interaction network development
To evaluate the interactions between the highly predictive
probe sets for ER class, we have employed the interaction
algorithm based on an ANN model described earlier [31]. Briefly,
from a set of 100 probes, 99 probe expression values (inputs) were
used to predict a single one (output). An ANN model was trained
until an optimal solution is found minimising the difference
between the expected output and the predicted. The weights for
the optimised model were recorded. This process was iteratively
repeated, selecting new inputs from the 100 set, until all probe
expressions are predicted from the remaining probes. The weights
quantify the intensity of the relation between source and target
which could be positive (stimulating) or negative (inhibiting). The
analysis generated a matrix of 9,900 bidirectional interactions for
all 100 probes. These were subsequently filtered to select the top
100 interactions for further visualisation.
The interaction network was visualised using CytoscapeH Ver
2.7.0 [32], which symbolised each probe set as a node and
interaction as an edge. To give directionality for the interactions
each input was considered as source, the output as target, and the
weights recorded for the prediction as interaction values. The
directionality for the edge is given according to source and target,
and the weight of the interaction is materialised by the thickness of
the edges.
Patient selection and immunohistochemistry
Tissue microarray (TMA) sections comprising 993 patients from
the Nottingham Tenovus study (1986–1998) with two tissue cores
represented from each patients tumour. TMA sections were
DACH1 is a Biomarker of Luminal A Breast Cancer
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immunostained to assess the protein expression levels of DACH1.
This TMA is well characterised with data for clinical information,
tissue protein expression of tumour-relevant pathological biomark-
ers and long term clinical follow-up including information on local,
regional and distant tumour recurrence, and cancer specific
survival outcome [10]. Patient management was based on the
Nottingham Prognostic Index (NPI) score and ER status as
previously described [33]. Breast cancer specific survival (BCSS)
was defined as the time (in months) from the date of the primary
surgical treatment to the time of death from breast cancer. Distant
metastasis free interval (DMFI) was defined as the interval (in
months) from the date of the primary surgical treatment to the
date of development of the first distant metastasis.
Four micron thick formalin fixed paraffin-processed TMA and
full face sections were subjected to microwave antigen retrieval in
citrate buffer (pH 6.0), and then immunohistochemically stained
with a rabbit polyclonal antibody against DACH1 (Sigma
HPA012672, St Louis, USA) using a streptavidin biotin technique
(Dako, Cambridge, UK). The DACH1 antibody was optimised for
heterogeneity and specificity at a working dilution of 1:200.
Sections were counterstained in haematoxylin and mounted using
DPX mounting medium. Negative controls comprising omission
of the primary antibody or substitution with an inappropriate
primary antibody of similar immunoglobulin class was used.
The immunohistochemically stained TMA sections were scored
with observers blinded to the clinicopathological features of
tumours and patients’ outcome. Nuclear staining intensity and
percentage of cells stained was assessed in unequivocal malignant
epithelium using the H-score (histochemical score) [34]. Staining
intensity was scored 0, 1, 2 or 3 and the percentage of positive cells
at each intensity subjectively estimated to produce a final score in
the range 0–300. Damaged tissue cores and those that did not
contain invasive carcinoma were censored.
Statistical Analysis
Statistical analysis was performed using SPSS 15.0 (SPSS Inc.,
Chicago, IL, USA) software. Three patient subgroups were
identified representing negative, low and high tumour nuclear
H-scores. The Kaplan-Meier method with a log rank test was used
to model the association of DACH1 group membership with
cancer specific survival. Patients were categorised using an H-score
$200 to define strong DACH1 positivity obtained in the majority
of cells in a patient’s tumour. Association between DACH1
expression and different clinicopathological factors and breast
cancer markers was evaluated using the non-parametric Chi-
Figure 1. DACH1 Interactome. The association of DACH1 with the 100 best predictive genes in ER-positive tumours. The genes are represented as
nodes and interactions as edges. The green edge is a positive interaction and the red edge is a negative interaction. The intensity of the interaction is
represented in terms of the thickness of edge and the directionality with the arrow.
doi:10.1371/journal.pone.0084428.g001
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square test. Patients that died due to causes other than breast
cancer were censored during survival analyses. Multivariate Cox
proportional hazard regression models were used to evaluate any
independent prognostic effect of the variables with 95%
confidence interval. A p-value of ,0.05 was considered to indicate
statistical significance.
Results
Identification of the ER interactome
Details of the gene signature associated with ER status were
recently published[22]. The best predictive probe sets for showing
association with ER status were selected based on lowest average
of test error encountered across 10 independent predictive models.
The best predictive probe was found to be 205225_at belonging to
ESR1 gene which codes for oestrogen receptor alpha (ERa). Other
highly predictive probe sets included GATA3, CA12 and NAT1
and DACH1 (205471_s_at).
Interaction network inference
The 100 best ER predictive probes selected from ER-positive
samples were further submitted to a network inference algorithm
to determine the strength and nature of interactions between the
selected probes. The algorithm yielded 9,702 interactions across
10 independent models. To reduce the dimensionality and to
remove insignificant interactions, a filtering strategy was applied to
select only the top 200 interactions based on interaction weight.
Bidirectional interactions were computed for any given pair of
genes accordingly to yield a bidirectional interaction matrix
between each source and target.
A network model of the top 200 (100 positive and 100 negative)
interactions forming positive and negative hubs is shown in Figure
S1. For example, DACH1 (Dachshund homolog 1), SERPINA 5
(Serpin peptidase inhibitor member 5), TFF3 (Trefoil factor 3),
and RARA (Retinoic acid receptor alpha) were connected with the
majority of positive interactions forming positive hubs. In contrast,
SOX11 (SRY (sex determining region Y)-box11), EGFR (Epider-
mal growth factor receptor) and CDH3 (cadherin 3, type 1, P-
cadherin) were connected with the majority of negative interac-
tions forming negative hubs. The strongest positive influence was
found between TFF1 (Trefoil factor 1) and TFF3, and the
strongest negative influence was found between MAPT (Microtu-
bule-associated protein tau) and EGFR.
To establish an interaction map with only DACH1 in luminal
(ER-positive) breast cancer samples, we created a DACH1
interactome (Figure 1) using the 100 best predictive genes.
Computationally, DACH1 was found to be highly positively
influenced by KIAA0882, a variant of TBC1 (tre-2/USP6, BUB2,
cdc16 domain 1) family member 9A, and highly negatively
influenced by IL6ST (Interleukin 6 signal transducer). DACH1
was also found to be highly positively and negatively influencing
CDH3 and SOX11 respectively. An interaction map (Figure S2)
of important genes overlapping with the oestrogen receptor and
DACH1 respectively, shows similarity.
DACH1 protein expression in breast cancer
To test the clinical relevance in breast cancer, the association of
DACH1 protein with clinicopathology features was investigated in
a well characterised patient cohort. The median age of the patients
was 55 years (range 27–70). DACH1 immunostaining was
localised to the nuclei of malignant cells and was found to be
Figure 2. Nuclear DACH1 immunostaining varied in intensity from being strong with expression in a high proportion of cells (a, b),
to weak (c) or negative (d), in breast carcinoma.
doi:10.1371/journal.pone.0084428.g002
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Table 1. Association of DACH1 expression with clinicopathological factors. N = number of samples. Statistically significant p-values
are in bold.
Clinical Parameter DACH1 absent DACH1 present Chi-square (X2) p-value
N % N %
Age group 12.505 0.006
,40 40 10.31 35 5.79
40–50 128 32.99 176 29.09
51–60 124 31.96 197 32.56
60–75 96 24.74 197 32.56
Menopause 8.912 0.003
Premenopausal 174 44.85 214 35.37
Postmenopausal 214 55.15 391 64.63
Tumour Size 2.283 0.131
#1.5 cm 178 46.23 307 51.17
.1.5 cm 207 53.77 293 48.83
Tumour Stage 0.413 0.813
1 241 62.27 362 60.23
2 112 28.94 183 30.45
3 34 8.79 56 9.32
Tumour Grade 69.335 ,0.001
1 35 9.09 134 22.33
2 94 24.42 226 37.67
3 256 66.49 240 40.00
Nottingham Prognostic Index 22.571 ,0.001
Good 75 19.48 200 33.28
Moderate 233 60.52 309 51.41
Poor 77 20.00 92 15.31
Tumour type 57.194 ,0.001
Ductal - Non Specific Type (NST) 260 68.60 314 53.04
Lobular (Classical and variants) 28 7.39 85 14.36
Tubular & Tubular mixed 50 13.19 136 22.97
Medullary 20 5.28 3 0.51
Special type (Mucinous, Cribriform and Invasive
papillary)
4 1.06 14 4.36
Mixed NST with Lobular and special types 17 4.49 40 6.76
Distant metastasis formation 0.349 0.555
Absent 268 69.43 425 71.19
Present 118 30.57 172 28.81
Tumour recurrence 0.078 0.780
Absent 231 60.63 353 59.73
Present 150 39.37 238 40.27
Vascular invasion 5.345 0.069
Negative 222 57.81 325 54.53
Probable 33 8.59 80 13.42
Definite 129 33.59 191 32.05
Endocrine therapy received 9.085 0.003
Untreated 261 71.12 331 61.41
Treated 106 28.88 208 38.59
doi:10.1371/journal.pone.0084428.t001
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either negative, weak or strong in intensity (Figure 2). DACH1 was
significantly increased in post-menopausal patients with lobular
and tubular cancer types but in contrast, was rarely seen in
patients with medullary cancer. DACH1 expression showed no
significant association with tumour size, tumour stage, metastasis
development, tumour recurrence, or vascular invasion. DACH1
expression was significantly increased in tumours of low grade,
good Nottingham Prognostic Index and candidacy for hormonal
therapy (Table 1).
Association of DACH1 with disease biomarkers
Nuclear DACH1 expression was strongly increased in patients
with ER-alpha positive tumours co-expressing PgR, and epithelial
CK18/19 cytokeratins. Nuclear staining was significantly associ-
ated with ‘luminal-like’ markers of good prognosis including
FOXA1 and RERG. In contrast, strong inverse associations were
found with candidate luminal markers of poor prognosis including
CD71 (Table 2).
Supporting its association with good prognosis, tumour DACH
1 expression correlated with low cell proliferation (MIB1). Low
DACH1 frequency and expression was seen in tumours bearing
markers of poor prognosis including the basal-like markers CK14/
5/6 and EGFR, as well as HER2 and p53 positivity.
Patients’ outcome
Patients with nuclear DACH1 positivity showed a significant
association with cancer specific survival (n = 81 (54%); x2= 11.96,
p,0.001), disease free interval (n = 81 (54%); x2=15.33,
p,0.001), tumour recurrence (n = 72 (52%); x2= 16.49,
p,0.001) and distant metastasis (n = 72 (51%); x2= 16.31,
p,0.001) over 5 years post diagnosis (Figure 3). However, the
level of significance lessened for predicting cancer specific survival
(x2= 2.31, p = 0.13), disease free interval (x2= 1.75, p = 0.17),
tumour recurrence (x2= 2.11, p = 0.15) and distant metastasis
(x2= 3.74, p= 0.053) over 10 years.
The effect of endocrine therapy on the ability of DACH1 to
predict breast cancer specific survival was considered using
Kaplan-Meier modelling. DACH1 positivity was associated with
good survival in patients treated with tamoxifen (x2 = 8.30,
p = 0.004) and in addition, also showed a trend in patients not
receiving tamoxifen (x2 = 3.7, p = 0.055).
The predictive independence of DACH1 was tested using
multivariate models (Cox regression) incorporating endocrine
therapy, clinical stage, tumour size and NPI status. DACH1 was
not found to be independent of these variables for predicting
cancer specific survival.
Discussion
In our study, we used an artificial neural network (ANN) based
inference technique to identify ER associated biomarkers capable
of separating good and poor prognosis patients with luminal type
breast cancer. Consistent with expectations, the best predictive
probe for identifying ER status in multiple independent runs was
205225_at representing ESR1 gene coding for oestrogen receptor
alpha. Moreover the regulatory gene DACH1, associated with
TGFb signalling, was identified among the probe sets that
produced a strongly positive interaction with ER status and so
we tested its relevance as a luminal marker of disease progression
by investigating its association with clinicopathologic variables.
The objective is to compile cumulative evidence to produce a
panel of markers capable of clinically guiding in the selection and
management of breast cancer patients within the heterogeneous
luminal class.




absent DACH1 present Chi-square
N % N % (X2) p-value
ER 142.867 ,0.001
Absent 181 49.45 78 13.66
Present 185 50.55 493 86.34
PgR 55.671 ,0.001
Absent 212 58.56 191 33.69
Present 150 41.44 376 66.31
CK18 54.282 ,0.001
Absent 86 24.86 39 7.21
Present 260 75.14 502 92.79
CK19 5.786 0.016
Absent 50 13.51 50 8.61
Present 320 86.49 531 91.39
HER2 6.595 0.010
Absent 311 83.38 524 89.12
Present 62 16.62 64 10.88
E-cadherin 0.853 0.356
Absent 145 40.06 213 37.04
Present 217 59.94 362 62.96
EGFR 6.371 0.012
Absent 249 76.62 425 83.66
Present 76 23.38 83 16.34
CK5/6 66.158 ,0.001
Absent 267 71.97 534 91.75
Present 104 28.03 48 8.25
CK14 11.671 0.001
Absent 304 82.83 518 90.40
Present 63 17.17 55 9.60
p53 33.999 ,0.001
Absent 227 62.71 457 80.04
Present 135 37.29 114 19.96
MIB1 28.563 ,0.001
Absent 59 29.95 154 54.61
Present 138 70.05 128 45.39
FOXA1 26.495 ,0.001
Absent 178 62.9 174 43.0
Present 105 37.1 231 57.0
CD71 25.926 ,0.001
Absent 90 32.4 220 51.9
Present 188 67.6 204 48.1
PELP1 0.375 0.540
Absent 250 87.4 369 85.8
Present 36 12.6 61 14.2
RERG 4.291 0.038
Absent 214 78.7 306 71.7
Present 58 21.3 121 28.3
doi:10.1371/journal.pone.0084428.t002
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We observed three predominant patterns of nuclear DACH1
expression compatible with TSG (tumour suppressor gene)
functionality. Nuclear DACH1 protein expression was significant-
ly associated with markers of good prognosis including low cellular
proliferation (MIB1 expression) and functional apoptosis (Bcl2
expression). It has previously been observed that reduced DACH1
expression occurs in invasive cancer compared to normal breast
epithelium confirmed by our findings where DACH1 expression
showed an inverse association with mitosis and cyclin D1
expression in breast cancer patient samples [26]. More recently,
increased DACH1 expression was reported to correlate with
reduced expression of IL-8 and other related chemokines, thus
inhibiting cellular migration and invasion in MCF10A breast
cancer cells [28]. Further evidence of its TSG function is provided
by the observation that DACH1 homozygous deletion stimulates
tumorigenesis in glioma cells [35], and loss of DACH1 occurs in
high FIGO surgical stage endometrial cancers [36]. Furthermore,
it has also recently been reported that over-expression of DACH1
protein is associated with poor prognosis when expressed in the
cytoplasm rather than nuclei of ovarian cancer cells indicating
disease progression [37], compatible with loss of TSG function. In
vitro cell signalling studies have shown that DACH1 exerts its
regulatory control on TGFb signalling by nuclear binding via
SMAD4 [26,38], competing with precancerous transcriptional
factors. Recent breast cancer studies have shown that DACH1 can
directly influence the gene expression of stem cells, causing them
to under-express CD24 [27]. In addition, it appears that the
tumour suppressor function of DACH1 can be moderated by the
tissue microenvironment including the presence of growth factors,
evidenced by tumorigenesis seen in cell lines grown in vitro in the
presence of IGF-1[39].
Steroid receptors, coactivators and co-repressors regulate the
activity of ERa. PELP1 (proline, glutamic acid and leucine rich
protein 1) is a coactivator that binds with the AF-2 domain
(oestrogen responsive element) of ERa, facilitating downstream
estradiol-induced DNA synthesis and cell proliferation [14].
Previously, we reported that PELP1 expression is associated with
larger tumours and clinicopathology features indicative of poor
prognosis, including high grade and basal cytokeratin expression
[13]. DACH1 competitively binds with ERa, preventing PELP1
binding [14]. In the current study we found that moderate to high
tumour nuclear DACH1 expression in the majority of cancer cells
is compatible with functionally blocking PELP1 activity, reflected
by its association with good prognosis. Conversely, absent or weak
DACH1 nuclear staining represents unopposed PELP1 mediated
tumour cell growth.
An inverse relationship was seen between DACH1 and basal
type markers including CK14, CK5/6 and EGFR. EGFR is a
member of the HER family associated with multiple downstream
cell signalling pathways leading to adverse clinical outcomes
including tumour growth and metastasis. In accord we found an
inverse association for DACH1 and HER2. In this respect and
similar to our previous report, we propose that DACH1 and
FOXA1 [33] share membership of the Luminal A biomarker
group in being associated with variables of good prognosis.
DACH1 was found to be a predictor of specific survival but was
not independent of hormonal therapy, clinical stage, tumour size
or NPI status. Clinical tests that identify high risk (increased
metastatic potential) patients with breast cancer to select
candidates for chemotherapy treatment are currently under
review [40]. Applying rationalised targeted treatment is necessary
because chemotherapy can result in medical complications,
Figure 3. Kaplan-Meier plots modelling DACH1 expression with 5 year post-diagnostic a) specific survival, b) tumour recurrence,
and c) distant metastasis. All were significant at p,0.001.
doi:10.1371/journal.pone.0084428.g003
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reduced quality of life and economic burden. Crucially, some
cancers present with no greater mortality risk if untreated with
chemotherapy and among these, patients with Luminal A cancers
appear to have good survival prospects (in press). Further
investigation is required to determine if DACH1 and other
Luminal A biomarkers can be used for selecting patients not
requiring chemotherapy.
As ANNs have a proven application in breast cancer patient
classification [22] and for biomarker identification associated with
disease progression [41], in the current study the focus for
relevance to clinical outcome has been exploited. Among the top
ten ranked genes with positive association to ER was the
transcription factor GATA3 known to be associated with ER
[42], ER status [21] and hormonal responsiveness in breast cancer
[43]. Genes showing a negative association with ER included
CA12 which is associated with hypoxia and poor prognosis in
breast cancer [44]. These findings and others in previous studies
support the validity and robustness of the ANN technique and its
application in identifying breast cancer biomarkers.
In summary, we have shown that DACH1 occurs in patients
with ER+ breast cancers and predicts good prognosis. In this
respect DACH1 can be regarded as a Luminal A biomarker.
Supporting Information
Figure S1 Interaction map of 2 (100 positive and 100
negative) interactions from highly predictive probe sets
in ER positive samples. The genes are represented as nodes
and interactions as edges. Green edge is a positive interaction and
red edge is a negative interaction. The intensity of the interaction
is represented in terms of the thickness of edge and the
directionality with the arrow from source to target. The nodes
with multiple interactions (.5) are considered as hubs.
(TIF)
Figure S2 Association of luminal markers with (a) ESR1
and (b) DACH1 in luminal samples. The genes are
represented as nodes and interactions as edges. The green edge
is a positive interaction and the red edge is a negative interaction.
The intensity of the interaction is represented in terms of the
thickness of edge and the directionality with the arrow.
(TIF)
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